Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GALT
stocks logo

GALT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast GALT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GALT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.300
sliders
Low
6.00
Averages
6.00
High
6.00
Current: 6.300
sliders
Low
6.00
Averages
6.00
High
6.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$6
2025-06-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$6
2025-06-18
initiated
Buy
Reason
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2025-04-02
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2025-04-02
Reiterates
Hold
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
to
Hold
Downgrades
n/a
2024-12-27
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2024-12-27
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Galectin Therapeutics Inc (GALT.O) is -13.26, compared to its 5-year average forward P/E of -3.48. For a more detailed relative valuation and DCF analysis to assess Galectin Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.48
Current PE
-13.26
Overvalued PE
-1.13
Undervalued PE
-5.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.04
Current PS
0.00
Overvalued PS
5.64
Undervalued PS
-3.55
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GALT News & Events

Events Timeline

(ET)
2025-11-14
08:08:15
Galectin Therapeutics announces Q4 earnings per share of 13 cents, compared to a loss of 18 cents last year.
select
2025-11-10 (ET)
2025-11-10
08:25:07
Galectin Therapeutics showcases NAVIGATE trial findings at AASLD
select
2025-08-18 (ET)
2025-08-18
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
09-25Benzinga
Stitch Fix Reports Q4 Earnings, Alongside Transocean, MBX Biosciences, and Other Major Stocks Declining in Thursday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by 0.1% on Thursday.

  • Stitch Fix Performance: Stitch Fix, Inc. shares fell 7.6% in pre-market trading despite reporting a smaller-than-expected quarterly loss and higher revenue than estimates.

  • Other Stocks Declining: Several other stocks, including Transocean Ltd. and Nanobiotix S.A., experienced significant declines in pre-market trading due to various announcements, including public offerings and study results.

  • Market Overview: Overall, multiple companies saw their stock prices drop in pre-market trading, reflecting a cautious market sentiment.

[object Object]
Preview
2.0
09-12NASDAQ.COM
Galectin Therapeutics Inc. (GALT) Sees 7.48% Increase Over the Past Week: Key Insights

  • Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify promising stocks based on price trends and earnings estimate revisions.

  • Galectin Therapeutics Inc. (GALT) Performance: GALT has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with significant price increases of 80.55% over the past quarter and 119.19% over the past year, outperforming the S&P 500.

  • Volume and Estimate Revisions: GALT's average 20-day trading volume is 251,038 shares, indicating bullish potential. Additionally, recent earnings estimate revisions have improved, suggesting positive momentum for the company.

  • Investment Recommendations: GALT is highlighted as a strong momentum pick, and investors are encouraged to consider it alongside other high-potential stocks identified by Zacks Investment Research.

[object Object]
Preview
9.0
09-12NASDAQ.COM
Stocks of MODD, GALT, XCUR, PEPG, and BSGM Surge in After-Hours Trading Following Clinical Developments and Strategic Actions

  • Modular Medical Inc. (MODD): The stock surged 30.68% to $0.9150 after announcing the completion of a clinical study for its MODD1 insulin pump and plans to submit its Pivot pump to the FDA in October 2025, alongside significant insider buying activity.

  • Galectin Therapeutics Inc. (GALT): The stock rose over 14% to $6.78, continuing a year-to-date gain of over 360%, with CEO Joel Lewis indicating ongoing analysis of biomarkers for their lead candidate, belapectin, which targets MASH cirrhosis and portal hypertension.

  • Exicure Inc. (XCUR): Shares increased 11.11% to $4.00 despite no new announcements, following a wider net loss reported for Q2 2025, as the company pivots its focus to new clinical directions after acquiring GPCR USA.

  • BioSig Technologies Inc. (BSGM): The stock gained 37.08% to $6.10, with an additional rise after announcing its rebranding to Streamex Corp. and a shift in focus towards real-world asset tokenization, including a partnership to develop tokenized gold products.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Galectin Therapeutics Inc (GALT) stock price today?

The current price of GALT is 6.3 USD — it has increased 10.53 % in the last trading day.

arrow icon

What is Galectin Therapeutics Inc (GALT)'s business?

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

arrow icon

What is the price predicton of GALT Stock?

Wall Street analysts forecast GALT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Galectin Therapeutics Inc (GALT)'s revenue for the last quarter?

Galectin Therapeutics Inc revenue for the last quarter amounts to -4.20M USD, decreased -53.70 % YoY.

arrow icon

What is Galectin Therapeutics Inc (GALT)'s earnings per share (EPS) for the last quarter?

Galectin Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Galectin Therapeutics Inc (GALT)'s fundamentals?

The market is revising No Change the revenue expectations for Galectin Therapeutics Inc. (GALT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 34.90%.
arrow icon

How many employees does Galectin Therapeutics Inc (GALT). have?

Galectin Therapeutics Inc (GALT) has 15 emplpoyees as of December 05 2025.

arrow icon

What is Galectin Therapeutics Inc (GALT) market cap?

Today GALT has the market capitalization of 406.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free